ELSEVIER

International Journal of Antimicrobial Agents 18 (2001) 587–592

INTERNATIONAL JOURNAL OF
Antimicrobial Agents

www.ischemo.org

Author index

Volume 18 (2001)

Abel, R., see Baum, H. **18**, 335
Abu El-Asrar, A.A., see Kadry, A.A. **18**, 55
Achour, A., The cationic amphiphilic molecules as potential immunostimulants for HIV-1 infection **18**, 274
Adrián, F., see Gómez-Lus, R. **18**, 49
Agel, A., see Maniatis, N. **18**, 407
Aguilar, L., see Prieto, J. **18**, 231
Akaike, Y., see Matsumoto, F. **18**, 471
Akalın, H.E., see Çetinkaya, Y. **18**, 1
Akçalı, S., see Tünger, Ö. **18**, 445
Akova, M., see Çetinkaya, Y. **18**, 1
Aksöyek, S., see Çetinkaya, Y. **18**, 1
Aksoy, H., see Tünger, Ö. **18**, 93
Alonzo, V., see Nostro, A. **18**, 305
Alonzo, V., see Nostro, A. **18**, 583
Alou, L., see Prieto, J. **18**, 231
Amaral, L. and J.E. Kristiansen, Phenothiazines: potential management of Creutzfeldt–Jacob disease and its variants **18**, 411
Ambler, J., see Lopez, H. **18**, 379
Angela Cannatelli, M., see Nostro, A. **18**, 583
Antunes, E.N.F., see Avelar, K.E.S. **18**, 129
Antunes, L.C.M., see Avelar, K.E.S. **18**, 129
Aoki, A., see Mori, N. **18**, 451
Arne Høiby, E., see Leegaard, T.M. **18**, 99
Arısoy, A., see Tünger, Ö. **18**, 445
Aşçıoğlu, S., see Çetinkaya, Y. **18**, 1
Atzori, C., G. Fantoni, A. Valerio and A. Cargnel, **18**, 271
Avelar, K.E.S., J.M.B.D. Vieira, L.C.M. Antunes, L.A. Lobo, E.N.F. Antunes, R.M.C.P. Domingues and M.C.S. Ferreira, Antimicrobial resistance of strains of the *Bacteroides fragilis* group isolated from the intestinal tract of children and adults in Brazil **18**, 129

Bacchiocchi, I., see Ottaviani, D. **18**, 135
Baka, M., see Maltezou, H.C. **18**, 383
Ball, P., T.M. File, M. Twynholm and T. Henkel, Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections **18**, 19
Baum, H., S. Böttcher, R. Abel, H.J. Gerner and H.-G. Sonntag, Tissue and serum concentrations of levofloxacin in orthopaedic patients **18**, 335
Beach, M.L., see Fix, A.M. **18**, 141
Bedenkov, A., see Stratchounski, L. **18**, 283
Beeck, A., see Schmitz, F.-J. **18**, 433
Benjamin, W.H., Jr, see Johnson, C.N. **18**, 531
Benjamin, W., Jr., see Zheng, X. **18**, 373
Bergan, T., Antibiotic usage in Nordic countries **18**, 279
Bernard, E., see Dellamonica, P. **18**, 299
Bevanger, L., see Leegaard, T.M. **18**, 99
Biedenbach, D.J., see Deshpande, L. **18**, 437
Biedenbach, D.J., see Fix, A.M. **18**, 141
Bisignano, G., see Nostro, A. **18**, 305
Blokhin, B.M., see Stratchounski, L.S. **18**, 347
Bon, I., see Re, M.C. **18**, 519
Bonner, D.P., see Fung-Tomc, J. **18**, 77
Bonner, D., see Gradelski, E. **18**, 43
Borderi, M., see Re, M.C. **18**, 519
Borner, E., see Borner, K. **18**, 253
Borner, K., E. Borner and H. Lode, Determination of linezolid in human serum and urine by high-performance liquid chromatography **18**, 253
Böttcher, S., see Baum, H. **18**, 335
Boyko, L.M., see Stratchounski, L.S. **18**, 347
Brandi, G., see Schiavano, G.F. **18**, 525
Briñas, L., see Sáenz, Y. **18**, 353
Brook, I., T.B. Elliott, H.I. Pryor, II, T.E. Sautter, B.T. Gnade, J.H. Thakar and G.B. Knudson, In vitro resistance of *Bacillus anthracis* Sterne to doxycycline, macrolides and quinolones **18**, 559
Burley, C.J., see Masterton, R.G. **18**, 503
Butts, J.D., see Ives, T.J. **18**, 217

Cannatelli, M.A., see Nostro, A. **18**, 305
Cardeñosa, O., see Lopez, H. **18**, 379
Cargnel, A., see Atzori, C. **18**, 271
Carraturo, A., see Ottaviani, D. **18**, 135
Caugant, D.A., see Leegaard, T.M. **18**, 99
Celeste, A.G., see Schiavano, G.F. **18**, 525
Celińska-Cedro, D., see Dzierżanowska-Fangrat, K. **18**, 387
Çetinkaya, Y., M. Akova, H.E. Akalın, S. Aşçıoğlu, M. Hayran, Ö. Uzuns, S. Aksöyek, L. Tokgözoğlu, A. Oto, S. Kes, İ. Paşaoğlu and S. Ünal, A retrospective review of 228 episodes of infective endocarditis where rheumatic valvular disease is still common **18**, 1
Chakrabarty, A.N., see Mazumder, R. **18**, 403
Chang, S.-C., see Fang, C.-T. **18**, 267
Chazan, B., see Colodner, R. **18**, 189
Chen, Y.-C., see Fang, C.-T. **18**, 267
Chiodo, F., see Re, M.C. **18**, 519
Choi, B.-K., K.-Y. Kim, Y.-J. Yoo, S.-J. Oh, J.-H. Choi and C.-Y. Kim, In vitro antimicrobial activity of a chitooligosaccharide mixture against *Actinobacillus actinomycetemcomitans* and *Streptococcus mutans* **18**, 553
Choi, J.-H., see Choi, B.-K. **18**, 553
Chow, C., see Kumarasinghe, G. **18**, 391
Chudnicka, A., see Kozioł-Montewka, M. **18**, 193
Chuma, T., see Niwa, H. **18**, 359
Cianflone, M., see Rondini, G. **18**, 9
Cieślik, A., see Szych, J. **18**, 37
Cocuzza, C.E., see Rondini, G. **18**, 9

PII: S0924-8579(01)00476-9

Collomb, R., see Dellamonica, P. **18**, 299
Colodner, R., Y. Keness, B. Chazan and R. Raz, Antimicrobial susceptibility of community-acquired uropathogens in northern Israel **18**, 189
Colwell, R.R., see Malekzadeh, F. **18**, 85
Crain, M.C., see Johnson, C.N. **18**, 531
Crain, M., see Zheng, X. **18**, 373
Crisafi, G., see Nostro, A. **18**, 583
Cris, G., see Nostro, A. **18**, 305
Critchley, I., see Karlowsky, J.A. **18**, 121

Dal-Ré, R., see Prieto, J. **18**, 231
Dastidar, S.G., see Mazumder, R. **18**, 403
Daza, R., J. Gutiérrez and G. Piédrola, Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections **18**, 211
De Anta, M.T.J., see Ruiz, J. **18**, 107
De Clercq, E., Hamao Umezawa Memorial Award Lecture: 'An Odyssey in the Viral Chemotherapy Field' **18**, 309
del Campo, R., see Gómez-Lus, R. **18**, 49
Dellamonica, P., P.M. Roger, A. Mousnier, R. Collomb, E. Bernard and T. Fosse, How to organise antibiotic prescription **18**, 299
D'Errico, G., see Esposito, S. **18**, 341
Deshpande, L., D.J. Biedenbach and R.N. Jones, Antimicrobial activity of BMS 284756 (T-3811) against *Neisseria gonorrhoeae* tested by three methods **18**, 437
Deshpande, L.M., A.C. Gales and R.N. Jones, GAR-936 (9-*t*-butylglycylamido-minocycline) susceptibility test development for streptococci, *Haemophilus influenzae* and *Neisseria gonorrhoeae*: preliminary guidelines and interpretive criteria **18**, 29
Dick, T., see Murugasu-Oei, B. **18**, 579
Domingues, R.M.C.P., see Avelar, K.E.S. **18**, 129
Domínguez, L., see Fernández, E.P. **18**, 571
Doron, S., M. Friedman, M. Falach, E. Sadovnic and H. Zvia, Antibacterial effect of parabens against planktonic and biofilm *Streptococcus sobrinus* **18**, 575
Dutt, M. and G.K. Khuller, Liposomes and PLG microparticles as sustained release antitubercular drug carriers—an in vitro–in vivo study **18**, 245
Dzierżanowska, D., see Dzierżanowska-Fangrat, K. **18**, 387
Dzierżanowska-Fangrat, K., E. Rożynek, P. Jóźwiak, D. Celińska-Cedro, K. Madaliński and D. Dzierżanowska, Primary resistance to clarithromycin in clinical strains of *Helicobacter pylori* isolated from children in Poland **18**, 387

Edwards, K.M., see Johnson, C.N. **18**, 531
Egorova, O.A., see Stratchounski, L.S. **18**, 347
Ehsanifar, H., see Malekzadeh, F. **18**, 85
Elliott, T.B., see Brook, I. **18**, 559
Esposito, S., S. Noviello, F. Ianniello and G. D'Errico, Short-course therapy with cefaclor for treatment of streptococcal pharyngotonsillitis **18**, 341

Falach, M., see Doron, S. **18**, 575
Fang, C.-T., S.-C. Chang, Y.-C. Chen, S.-M. Hsieh and W.-C. Hsieh, In vitro activity of linezolid against clinical Gram-positive bacterial isolates from Taiwan: an area with a high prevalence of antibiotic resistance **18**, 267
Fantoni, G., see Atzori, C. **18**, 271
Ferenczy, L., see Kawase, M. **18**, 161
Fernández, E.P., A.I. Vela, A. Las Heras, L. Domínguez, J.F. Fernández-Garayzábal and M.A. Moreno, Antimicrobial susceptibility of corynebacteria isolated from ewe's mastitis **18**, 571
Fernández-Garayzábal, J.F., see Fernández, E.P. **18**, 571
Ferreira, M.C.S., see Avelar, K.E.S. **18**, 129
File, T.M., see Ball, P. **18**, 19
Fix, A.M., M.A. Pfaller, D.J. Biedenbach, M.L. Beach and R.N. Jones, Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development **18**, 141
Fluit, A.C., F.J. Schmitz and J. Verhoef, Multi-resistance to antimicrobial agents for the ten most frequently isolated bacterial pathogens **18**, 147
Fluit, A.C., see Schmitz, F.-J. **18**, 433
Fortunato, L., see Re, M.C. **18**, 519
Fosse, T., see Dellamonica, P. **18**, 299
Foustoukou, M., see Kanellopoulou, M. **18**, 179
Frías, J., see Prieto, J. **18**, 231
Friedman, M., see Doron, S. **18**, 575
Fuentes, F., see Prieto, J. **18**, 231
Fujimoto, M., Pharmacokinetics of cefcapene pivoxil and AS-924 in gastrectomized patients **18**, 489
Fukumoto, R., see Nimura, K. **18**, 173
Fung-Tomc, J., E. Gradelski, E. Huczko, B. Minassian and D.P. Bonner, Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants **18**, 77
Fung-Tomc, J., see Gradelski, E. **18**, 43

Gabriel, L., see Souli, M. **18**, 239
Galanakis, N., see Sambatakou, H. **18**, 441
Gales, A.C., see Deshpande, L.M. **18**, 29
Ganguly, K., see Mazumder, R. **18**, 403
García, C., see Gómez-Lus, R. **18**, 49
Georgiou, N.A., T. van der Bruggen, C.A. Jansen, M. Oudshoorn, H.S.L.M. Nottet, J.J.M. Marx and B.S. van Asbeck, The chemotherapeutic agent bleomycin in a two-drug combination with zidovudine, ritonavir or indinavir synergistically inhibits HIV Type-1 replication in peripheral blood lymphocytes **18**, 513
Gerçeker, A.A., see Karakoç, B. **18**, 567
Germanò, M.P., see Nostro, A. **18**, 305
Gerner, H.J., see Baum, H. **18**, 335
Giamarellos-Bourboulis, E.J., see Sambatakou, H. **18**, 441
Giamarellou, H., see Sambatakou, H. **18**, 441
Giamarellou, H., see Souli, M. **18**, 239
Giammarioli, M., see Ottaviani, D. **18**, 135
Gibellini, D., see Re, M.C. **18**, 519
Gilbert, G.L., see Sintchenko, V. **18**, 223
Giménez, M.J., see Prieto, J. **18**, 231
Gnade, B.T., see Brook, I. **18**, 559
Gombakis, N., see Maltezou, H.C. **18**, 383
Gómez-Lus, P., see Gómez-Lus, R. **18**, 49
Gómez-Lus, R., F. Adrián, R. del Campo, P. Gómez-Lus, S. Sánchez, C. García and M.C. Rubio, Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of *Legionella* spp. **18**, 49
Gorini, R., see Re, M.C. **18**, 519
Gradelski, E., L. Valera, B. Kolek, D. Bonner and J. Fung-Tomc, Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and β-lactams **18**, 43
Gradelski, E., see Fung-Tomc, J. **18**, 77
Gray, B.M., see Johnson, C.N. **18**, 531
Grüger, T., see Stock, I. **18**, 537
Gutiérrez, J., see Daza, R. **18**, 211

Hamilton-Miller, J.M.T. and S. Shah, Identity and antibiotic susceptibility of enterobacterial flora of salad vegetables **18**, 81
Hand, D.L., see Hand, W.L. **18**, 419
Hand, W.L. and D.L. Hand, Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes **18**, 419

Hatano, S., see Mori, N. **18**, 451
Hatzi, F., see Petinaki, E. **18**, 61
Hatzi, F., see Petinaki, E. **18**, 563
Hayran, M., see Çetinkaya, Y. **18**, 1
Henkel, T., see Ball, P. **18**, 19
Henwood, C.J., see Johnson, A.P. **18**, 73
Hollingshead, S., see Zheng, X. **18**, 373
Hryniewicz, W., see Stratchounski, L. **18**, 283
Hsieh, S.-M., see Fang, C.-T. **18**, 267
Hsieh, W.-C., see Fang, C.-T. **18**, 267
Huczko, E., see Fung-Tomc, J. **18**, 77

Ianniello, F., see Esposito, S. **18**, 341
Iredell, J.R., see Sintchenko, V. **18**, 223
Ishiduka, S., see Nimura, K. **18**, 173
Itoh, K., see Niwa, H. **18**, 359
Ives, T.J., E.L. Marston, R.L. Regnery and J.D. Butts, In vitro susceptibilities of *Bartonella* and *Rickettsia* spp. to fluoroquinolone antibiotics as determined by immunofluorescent antibody analysis of infected Vero cell monolayers **18**, 217

Jansen, C.A., see Georgiou, N.A. **18**, 513
Jansze, M., see Mascini, E.M. **18**, 395
Jeljaszewicz, J., see Mlynarczyk, G. **18**, 497
Johnson, A.P., C.J. Henwood, L. Tysall and M. Warner, Activity of the ketolide telithromycin (HMR-3647) against erythromycin-susceptible and -resistant pneumococci isolated in the UK **18**, 73
Johnson, C.N., W.H. Benjamin, Jr, B.M. Gray, M.C. Crain, K.M. Edwards and K.B. Waites, In vitro activity of ABT-773, telithromycin and eight other antimicrobials against erythromycin-resistant *Streptococcus pneumoniae* respiratory isolates of children **18**, 531
Johnson, C., see Zheng, X. **18**, 373
Johnston, A.M., Animals and antibiotics **18**, 291
Jones, M.E., see Karlowsky, J.A. **18**, 121
Jones, R.N., see Deshpande, L. **18**, 437
Jones, R.N., see Deshpande, L.M. **18**, 29
Jones, R.N., see Fix, A.M. **18**, 141
Jones, R.N., see Shen, D. **18**, 185
Jóźwiak, P., see Dzierżanowska-Fangrat, K. **18**, 387
Jureen, R., see Leegaard, T.M. **18**, 99

Kadry, A.A., A.-K.F. Tawfik, A.A. Abu El-Asrar and A.M. Shibl, Elucidation of antibiotic effectiveness against *Staphylococcus epidermidis* during intraocular lens implantation **18**, 55
Kafetzis, D.A., see Maltezou, H.C. **18**, 383
Kałużewski, S., see Szych, J. **18**, 37
Kanamoto, T., see Kawase, M. **18**, 161
Kandalov, M.M., see Stratchounski, L.S. **18**, 347
Kanellopoulou, M., G. Stamos, I. Petinnelli, M. Savala, A. Tzimogianni, N.J. Legakis, M. Foustoukou, E. Papafragas and A. Velegraki, Subtyping and antifungal susceptibilities of *Candida* spp. in the intensive care unit of a Greek general hospital **18**, 179
Kano, T., see Yanagawa, A. **18**, 483
Karakoç, B. and A.A. Gerçeker, In-vitro activities of various antibiotics, alone and in combination with amikacin against *Pseudomonas aeruginosa* **18**, 567
Karlowsky, J.A., M.E. Jones, C. Thornsberry, I. Critchley, L.J. Kelly and D.F. Sahm, Prevalence of antimicrobial resistance among urinary tract pathogens isolated from female outpatients across the US in 1999 **18**, 121
Kasai, M., see Mori, N. **18**, 451
Kavouklis, E., see Souli, M. **18**, 239
Kawase, M., N. Motohashi, H. Sakagami, T. Kanamoto, H. Nakashima, L. Ferenczy, K. Wolfard, C. Miskolci and J. Molnár, Antimicrobial activity of trifluoromethyl ketones and their synergism with promethazine **18**, 161
Kelly, L.J., see Karlowsky, J.A. **18**, 121
Keness, Y., see Colodner, R. **18**, 189
Kes, S., see Çetinkaya, Y. **18**, 1
Khuller, G.K., see Dutt, M. **18**, 245
Kim, C.-Y., see Choi, B.-K. **18**, 553
Kim, K.-Y., see Choi, B.-K. **18**, 553
Kitagawa, M., see Mori, N. **18**, 451
Kitamura, T., see Yanagawa, A. **18**, 483
Knudson, G.B., see Brook, I. **18**, 559
Kodama, T., see Mori, N. **18**, 451
Kolek, B., see Gradelski, E. **18**, 43
Koliouskas, D.E., see Maltezou, H.C. **18**, 383
Kontos, F., see Petinaki, E. **18**, 61
Kontos, F., see Petinaki, E. **18**, 563
Kopsinis, G., see Souli, M. **18**, 239
Kosmidou, H., see Maltezou, H.C. **18**, 383
Kozioł-Montewka, M., A. Chudnicka, A. Książek and M. Majdan, Rate of *Staphylococcus aureus* nasal carriage in immunocompromised patients receiving haemodialysis treatment **18**, 193
Krcmery, V., see Stratchounski, L. **18**, 283
Kretchikova, O.I., see Stratchounski, L.S. **18**, 347
Kristiansen, J.E., see Amaral, L. **18**, 411
Książek, A., see Kozioł-Montewka, M. **18**, 193
Kubo, A., see Totsuka, K. **18**, 477
Kubo, A., see Totsuka, K. **18**, 463
Kumarasinghe, G., C. Chow and P.A. Tambyah, Widespread resistance to new antimicrobials in a university hospital before clinical use **18**, 391
Kurutepe, S., see Tünger, Ö. **18**, 445

Lantero, M., see Sáenz, Y. **18**, 353
Lanzafame, A., see Rondini, G. **18**, 9
La Placa, M., see Re, M.C. **18**, 519
Larsen, H., G.L. Nielsen, H.C. Schønheyder, C. Olesen and H.T. Sørensen, Birth outcome following maternal use of fluoroquinolones **18**, 259
Las Heras, A., see Fernández, E.P. **18**, 571
Leegaard, T.M., L. Bevanger, R. Jureen, T. Lier, K.K. Melby, D.A. Caugant, L. Oddvar Frøholm and E. Arne Høiby, Antibiotic sensitivity still prevails in Norwegian blood culture isolates **18**, 99
Legakis, N.J., see Kanellopoulou, M. **18**, 179
Legakis, N.J., see Maniatis, N. **18**, 407
Lehn, N., see Onda, H. **18**, 263
Leitch, E.C. and M.D.P. Willcox, Lactoferrin-induced reduction of *vanB* vancomycin resistance in enterococci **18**, 399
Lemme, L., see Lopez, H. **18**, 379
Leoni, F., see Ottaviani, D. **18**, 135
Levin, M., see Malekzadeh, F. **18**, 85
Lier, T., see Leegaard, T.M. **18**, 99
Li, J.T., see Zhang, Y.L. **18**, 365
Lobo, L.A., see Avelar, K.E.S. **18**, 129
Lode, H., Role of sultamicillin and ampicillin/sulbactam in the treatment of upper and lower bacterial respiratory tract infections **18**, 199
Lode, H., see Borner, K. **18**, 253
Lopez, H., V. Vilches, S. Scarano, D. Stepanik, J. Smayevsky, L. Lemme, O. Cardeñosa, J. Ambler and A. Sucari, Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens **18**, 379
Ludwig, E., see Stratchounski, L. **18**, 283
Lu, Y., see Zheng, X. **18**, 373

Madaliński, K., see Dzierżanowska-Fangrat, K. **18**, 387
Majdan, M., see Kozioł-Montewka, M. **18**, 193
Malaka-Zafiriou, E., see Maltezou, H.C. **18**, 383
Malekzadeh, F., H. Ehsanifar, M. Shahamat, M. Levin and R.R. Colwell, Antibacterial activity of black myrobalan (*Terminalia chebula* Retz) against *Helicobacter pylori* **18**, 85

Maltezou, H.C., M. Baka, N. Gombakis, D.E. Koliouskas, H. Kosmidou, E. Malaka-Zafiriou and D.A. Kafetzis, Comparison of isepamicin with amikacin for the empirical treatment of febrile neutropenic children with malignancies **18**, 383
Maniati, M., see Petinaki, E. **18**, 61
Maniati, M., see Petinaki, E. **18**, 563
Maniatis, A.N., see Petinaki, E. **18**, 61
Maniatis, A.N., see Petinaki, E. **18**, 563
Maniatis, N., A. Agel, N.J. Legakis and L.S. Tzouvelekis, Mupirocin resistance in *Staphylococcus aureus* from Greek hospitals **18**, 407
Margutti, P., see Visconti, E. **18**, 547
Marinaci, S., see Visconti, E. **18**, 547
Marston, E.L., see Ives, T.J. **18**, 217
Marx, J.J.M., see Georgiou, N.A. **18**, 513
Mascini, E.M., M. Jansze, L.M. Schouls, J. Verhoef and H. Van Dijk, Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci **18**, 395
Masini, L., see Ottaviani, D. **18**, 135
Masterton, R.G. and C.J. Burley, Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis **18**, 503
Matsumoto, F., I. Sakurai, M. Morita, T. Takahashi, N. Mori, T. Sugihara, A. Sakai, S. Yamaji, Y. Akaike and K. Yano, Effects of the quantity of water and milk ingested concomitantly with AS-924, a novel ester-type cephem antibiotic, on its pharmacokinetics **18**, 471
Mattina, R., see Rondini, G. **18**, 9
Mazumder, R., K. Ganguly, S.G. Dastidar and A.N. Chakrabarty, Trifluoperazine: a broad spectrum bactericide especially active on staphylococci and vibrios **18**, 403
McNulty, C.A.M., Optimising antibiotic prescribing in primary care **18**, 329
Melby, K.K., see Leegaard, T.M. **18**, 99
Mencarini, P., see Visconti, E. **18**, 547
Michisuji, Y., see Totsuka, K. **18**, 477
Michisuji, Y., see Totsuka, K. **18**, 463
Minassian, B., see Fung-Tomc, J. **18**, 77
Miriagou, V., see Petinaki, E. **18**, 61
Miriagou, V., see Petinaki, E. **18**, 563
Miskolci, C., see Kawase, M. **18**, 161
Mlynarczyk, A., see Mlynarczyk, G. **18**, 497
Mlynarczyk, G., A. Mlynarczyk and J. Jeljaszewicz, Epidemiological aspects of antibiotic resistance in respiratory pathogens **18**, 497
Molnár, J., see Kawase, M. **18**, 161
Molnár, J., see Mucsi, I. **18**, 67
Monari, P., see Re, M.C. **18**, 519
Moreno, M.A., see Fernández, E.P. **18**, 571
Mori, N., see Matsumoto, F. **18**, 471
Mori, N., see Totsuka, K. **18**, 477
Mori, N., see Totsuka, K. **18**, 463
Mori, N., see Yanagawa, A. **18**, 483
Mori, N., T. Kodama, A. Sakai, T. Suzuki, T. Sugihara, S. Yamaguchi, T. Nishijima, A. Aoki, M. Toriya, M. Kasai, S. Hatano, M. Kitagawa, A. Yoshimi and K.-i. Nishimura, AS-924, a novel, orally active, bifunctional prodrug of ceftizoxime: physicochemical properties, oral absorption in animals, and antibacterial activity **18**, 451
Morita, M., see Matsumoto, F. **18**, 471
Motohashi, N., see Kawase, M. **18**, 161
Motohashi, N., see Mucsi, I. **18**, 67
Mousnier, A., see Dellamonica, P. **18**, 299
Mucsi, I., J. Molnár and N. Motohashi, Combination of benzo[*a*]phenothiazines with acyclovir against herpes simplex virus **18**, 67
Murugasu-Oei, B. and T. Dick, In vitro activity of the chelating agents nitroxoline and oxine against *Mycobacterium bovis* BCG **18**, 579
Naber, K.G., see Onda, H. **18**, 263
Nakashima, H., see Kawase, M. **18**, 161
Nielsen, G.L., see Larsen, H. **18**, 259
Nimura, K., Y. Niwano, S. Ishiduka and R. Fukumoto, Comparison of in vitro antifungal activities of topical antimycotics launched in 1990s in Japan **18**, 173
Nishijima, T., see Mori, N. **18**, 451
Nishimura, K.-i., see Mori, N. **18**, 451
Niwa, H., T. Chuma, K. Okamoto and K. Itoh, Rapid detection of mutations associated with resistance to erythromycin in *Campylobacter jejuni/coli* by PCR and line probe assay **18**, 359
Niwano, Y., see Nimura, K. **18**, 173
Nostro, A., G. Bisignano, M.A. Cannatelli, G. Cris, M.P. Germanò and V. Alonzo, Erratum to "Effects of *Helichrysum italicum* extract on growth and enzymatic activity of *Staphylococcus aureus*": [Int. J. Antimicrob. Agents 17 (2001) 517–520] **18**, 305
Nostro, A., M. Angela Cannatelli, G. Crisafi and V. Alonzo, The effect of *Nepeta cataria* extract on adherence and enzyme production of *Staphylococcus aureus* **18**, 583
Nottet, H.S.L.M., see Georgiou, N.A. **18**, 513
Noviello, S., see Esposito, S. **18**, 341

Oddvar Frøholm, L., see Leegaard, T.M. **18**, 99
Oh, S.-J., see Choi, B.-K. **18**, 553
Okamoto, K., see Niwa, H. **18**, 359
Olesen, C., see Larsen, H. **18**, 259
Onda, H., F.M.E. Wagenlehner, N. Lehn and K.G. Naber, In vitro activity of linezolid against Gram-positive uropathogens of hospitalized patients with complicated urinary tract infections **18**, 263
Ortona, E., see Visconti, E. **18**, 547
Orús, P. and M. Viñas, Mechanisms other than penicillin-binding protein-2 alterations may contribute to moderate penicillin resistance in *Neisseria meningitidis* **18**, 113
Oto, A., see Çetinkaya, Y. **18**, 1
Ottaviani, D., I. Bacchiocchi, L. Masini, F. Leoni, A. Carraturo, M. Giammarioli and G. Sbaraglia, Antimicrobial susceptibility of potentially pathogenic halophilic vibrios isolated from seafood **18**, 135
Oudshoorn, M., see Georgiou, N.A. **18**, 513
Özbakkaloğlu, B., see Tünger, Ö. **18**, 445
Özbakkaloğlu, B., see Tünger, Ö. **18**, 93

Paciorek, J., see Szych, J. **18**, 37
Papafragas, E., see Kanellopoulou, M. **18**, 179
Paşaoğlu, İ., see Çetinkaya, Y. **18**, 1
Perdikouli, M., see Schmitz, F.-J. **18**, 433
Petinaki, E., F. Kontos, V. Miriagou, M. Maniati, F. Hatzi and A.N. Maniatis, Survey of methicillin-resistant coagulase-negative staphylococci in the hospitals of central Greece **18**, 563
Petinaki, E., V. Miriagou, L.S. Tzouvelekis, S. Pournaras, F. Hatzi, F. Kontos, M. Maniati and A.N. Maniatis, Methicillin-resistant *Staphylococcus aureus* in the hospitals of Central Greece **18**, 61
Petinnelli, I., see Kanellopoulou, M. **18**, 179
Pfaller, M.A., see Fix, A.M. **18**, 141
Piédrola, G., see Daza, R. **18**, 211
Pournaras, S., see Petinaki, E. **18**, 61
Prieto, J., L. Aguilar, F. Fuentes, M.J. Giménez, L. Alou, R. Dal-Ré, F. Sörgel and J. Frías, Influence of diminished susceptibility of *Streptococcus pneumoniae* to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers **18**, 231
Pryor, H.I., II, see Brook, I. **18**, 559

Raz, R., see Colodner, R. **18**, 189
Regnery, R.L., see Ives, T.J. **18**, 217
Reisman, A., see Treadway, G. **18**, 427

Re, M.C., M. Borderi, P. Monari, I. Bon, R. Gorini, D. Gibellini, G. Verucchi, L. Fortunato, F. Chiodo and M. La Placa, Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a cohort of Italian HIV-1 seropositive patients extensively treated with antiretroviral drugs **18**, 519
Reshedko, G.K., see Stratchounski, L.S. **18**, 347
Roger, P.M., see Dellamonica, P. **18**, 299
Rondini, G., C.E. Cocuzza, M. Cianflone, A. Lanzafame, L. Santini and R. Mattina, Bacteriological and clinical efficacy of various antibiotics used in the treatment of streptococcal pharyngitis in Italy. An epidemiological study **18**, 9
Rożynek, E., see Dzierżanowska-Fangrat, K. **18**, 387
Rubio, M.C., see Gómez-Lus, R. **18**, 49
Ruiz, J., J.M. Sierra, M.T.J. De Anta and J. Vila, Characterization of sparfloxacin-resistant mutants of *Staphylococcus aureus* obtained in vitro **18**, 107
Ruiz-Larrea, F., see Sáenz, Y. **18**, 353
Ryabkova, E.L., see Stratchounski, L.S. **18**, 347

Sadovnic, E., see Doron, S. **18**, 575
Sáenz, Y., M. Zarazaga, L. Briñas, M. Lantero, F. Ruiz-Larrea and C. Torres, Antibiotic resistance in *Escherichia coli* isolates obtained from animals, foods and humans in Spain **18**, 353
Sahm, D.F., see Karlowsky, J.A. **18**, 121
Sakagami, H., see Kawase, M. **18**, 161
Sakai, A., see Matsumoto, F. **18**, 471
Sakai, A., see Mori, N. **18**, 451
Sakai, A., see Totsuka, K. **18**, 477
Sakai, A., see Totsuka, K. **18**, 463
Sakai, A., see Yanagawa, A. **18**, 483
Sakurai, I., see Matsumoto, F. **18**, 471
Salvaggio, L., see Schiavano, G.F. **18**, 525
Sambatakou, H., E.J. Giamarellos-Bourboulis, N. Galanakis and H. Giamarellou, Pharmacokinetics of fluoroquinolones in uncompensated cirrhosis: the significance of penetration in the ascitic fluid **18**, 441
Sánchez, S., see Gómez-Lus, R. **18**, 49
Santini, L., see Rondini, G. **18**, 9
Sautter, T.E., see Brook, I. **18**, 559
Savala, M., see Kanellopoulou, M. **18**, 179
Sbaraglia, G., see Ottaviani, D. **18**, 135
Scarano, S., see Lopez, H. **18**, 379
Schiavano, G.F., A.G. Celeste, L. Salvaggio, M. Sisti and G. Brandi, Efficacy of macrolides used in combination with ethambutol, with or without other drugs, against *Mycobacterium avium* within human macrophages **18**, 525
Schmitz, F.-J., M. Perdikouli, A. Beeck, J. Verhoef and A.C. Fluit, Molecular surveillance of macrolide, tetracycline and quinolone resistance mechanisms in 1191 clinical European *Streptococcus pneumoniae* isolates **18**, 433
Schmitz, F.J., see Fluit, A.C. **18**, 147
Schønheyder, H.C., see Larsen, H. **18**, 259
Schouls, L.M., see Mascini, E.M. **18**, 395
Semenov, V., see Stratchounski, L. **18**, 283
Shahamat, M., see Malekzadeh, F. **18**, 85
Shah, S., see Hamilton-Miller, J.M.T. **18**, 81
Shen, D., P. Winokur and R.N. Jones, Characterization of extended spectrum β-lactamase-producing *Klebsiella pneumoniae* from Beijing, China **18**, 185
Shibl, A.M., see Kadry, A.A. **18**, 55
Shimada, J., see Yanagawa, A. **18**, 483
Shimizu, K., see Totsuka, K. **18**, 477
Shimizu, K., see Totsuka, K. **18**, 463
Shinohara, Y., see Totsuka, K. **18**, 477
Shinohara, Y., see Totsuka, K. **18**, 463
Sierra, J.M., see Ruiz, J. **18**, 107
Sintchenko, V., J.R. Iredell and G.L. Gilbert, Antibiotic therapy of ventilator-associated pneumonia—a reappraisal of rationale in the era of bacterial resistance **18**, 223
Siracusano, A., see Visconti, E. **18**, 547
Sisti, M., see Schiavano, G.F. **18**, 525
Smayevsky, J., see Lopez, H. **18**, 379
Sonntag, H.-G., see Baum, H. **18**, 335
Sörgel, F., see Prieto, J. **18**, 231
Souli, M., G. Kopsinis, E. Kavouklis, L. Gabriel and H. Giamarellou, Vancomycin levels in human aqueous humour after intravenous and subconjunctival administration **18**, 239
Sørensen, H.T., see Larsen, H. **18**, 259
Stamos, G., see Kanellopoulou, M. **18**, 179
Stepanik, D., see Lopez, H. **18**, 379
Stetsiouk, O.U., see Stratchounski, L.S. **18**, 347
Stock, I., T. Grüger and B. Wiedemann, Natural antibiotic susceptibility of strains of the *Enterobacter cloacae* complex **18**, 537
Stratchounski, L., A. Bedenkov, W. Hryniewicz, V. Krcmery, E. Ludwig and V. Semenov, The usage of antibiotics in Russia and some countries in Eastern Europe **18**, 283
Stratchounski, L.S., O.I. Kretchikova, G.K. Reshedko, O.U. Stetsiouk, M.M. Kandalov, O.A. Egorova, L.M. Boyko, E.L. Ryabkova, G.D. Tarasova and B.M. Blokhin, Antimicrobial susceptibility of nasopharyngeal isolates of *Haemophilus influenzae* from healthy children in day-care centres: results of multicentre study in Russia **18**, 347
Sucari, A., see Lopez, H. **18**, 379
Sugihara, T., see Matsumoto, F. **18**, 471
Sugihara, T., see Mori, N. **18**, 451
Sugihara, T., see Totsuka, K. **18**, 477
Sugihara, T., see Totsuka, K. **18**, 463
Sugihara, T., see Yanagawa, A. **18**, 483
Suzuki, T., see Mori, N. **18**, 451
Szkaradkiewicz, A. and M. Wal, Effect of cyclosporin on uropathogenic *Escherichia coli* adherence to human endothelial cells **18**, 89
Szych, J., A. Cieślik, J. Paciorek and S. Kałużewski, Antibiotic resistance in *Salmonella enterica* subsp. *enterica* strains isolated in Poland from 1998 to 1999 **18**, 37

Takahashi, T., see Matsumoto, F. **18**, 471
Tamburrini, E., see Visconti, E. **18**, 547
Tambyah, P.A., see Kumarasinghe, G. **18**, 391
Tarasova, G.D., see Stratchounski, L.S. **18**, 347
Tawfik, A.-K.F., see Kadry, A.A. **18**, 55
Thakar, J.H., see Brook, I. **18**, 559
Thornsberry, C., see Karlowsky, J.A. **18**, 121
Tokgözoğlu, L., see Çetinkaya, Y. **18**, 1
Tokuoka, H., see Totsuka, K. **18**, 477
Tokuoka, H., see Totsuka, K. **18**, 463
Toriya, M., see Mori, N. **18**, 451
Torres, C., see Sáenz, Y. **18**, 353
Totsuka, K., K. Shimizu, N. Mori, T. Sugihara, A. Sakai, S. Yamaji, Y. Michisuji, Y. Shinohara, A. Kubo and H. Tokuoka, Effect of antacid pretreatment on the pharmacokinetics of AS-924, a novel ester-type cephem antibiotic—comparison with cefteram-pivoxil **18**, 477
Totsuka, K., K. Shimizu, N. Mori, T. Sugihara, A. Sakai, S. Yamaji, Y. Michisuji, Y. Shinohara, A. Kubo and H. Tokuoka, Effects of food intake and age on the pharmacokinetics of AS-924, a novel ester-type cephem antibiotic. Comparison with cefpodoxime proxetil **18**, 463
Treadway, G. and A. Reisman, Tolerability of 3-day, once-daily azithromycin suspension versus standard treatments for community-acquired paediatric infectious diseases **18**, 427
Tünger, Ö., A. Arısoy, S. Kurutepe, S. Akçalı and B. Özbakkaloğlu, In vitro susceptibility of *Staphylococcus aureus* and coagulase-negative *Staphylococcus* strains to fusidic acid **18**, 445

Tünger, Ö., B. Özbakkaloğlu and H. Aksoy, Trends in antimicrobial resistant staphylococci in an university hospital over a 6-year period **18**, 93
Twynholm, M., see Ball, P. **18**, 19
Tysall, L., see Johnson, A.P. **18**, 73
Tzimogianni, A., see Kanellopoulou, M. **18**, 179
Tzouvelekis, L.S., see Maniatis, N. **18**, 407
Tzouvelekis, L.S., see Petinaki, E. **18**, 61

Uchida, K., N. Yokota and H. Yamaguchi, In vitro antifungal activity of posaconazole against various pathogenic fungi **18**, 167
Ünal, S., see Çetinkaya, Y. **18**, 1
Uzuns, Ö., see Çetinkaya, Y. **18**, 1

Valera, L., see Gradelski, E. **18**, 43
Valerio, A., see Atzori, C. **18**, 271
van Asbeck, B.S., see Georgiou, N.A. **18**, 513
van der Bruggen, T., see Georgiou, N.A. **18**, 513
Van Dijk, H., see Mascini, E.M. **18**, 395
Vela, A.I., see Fernández, E.P. **18**, 571
Velegraki, A., see Kanellopoulou, M. **18**, 179
Verhoef, J., see Fluit, A.C. **18**, 147
Verhoef, J., see Mascini, E.M. **18**, 395
Verhoef, J., see Schmitz, F.-J. **18**, 433
Verucchi, G., see Re, M.C. **18**, 519
Vieira, J.M.B.D., see Avelar, K.E.S. **18**, 129
Vila, J., see Ruiz, J. **18**, 107
Vilches, V., see Lopez, H. **18**, 379
Viñas, M., see Orús, P. **18**, 113
Visconti, E., E. Ortona, P. Mencarini, P. Margutti, S. Marinaci, M. Zolfo, A. Siracusano and E. Tamburrini, Mutations in dihydropteroate synthase gene of *Pneumocystis carinii* in HIV patients with *Pneumocystis carinii* pneumonia **18**, 547

Wagenlehner, F.M.E., see Onda, H. **18**, 263
Waites, K.B., see Johnson, C.N. **18**, 531
Waites, K.B., see Zheng, X. **18**, 373
Wal, M., see Szkaradkiewicz, A. **18**, 89
Warner, M., see Johnson, A.P. **18**, 73
Wiedemann, B., see Stock, I. **18**, 537
Wierup, M., The experience of reducing antibiotics used in animal production in the Nordic countries **18**, 287
Willcox, M.D.P., see Leitch, E.C. **18**, 399
Williams, J.D., Antibiotic resistance in hospital pathogens—acquisition or spread? **18**, 295
Williams, J.D., Tom Bergan (1939–2001) **18**, 277
Winokur, P., see Shen, D. **18**, 185
Wolfard, K., see Kawase, M. **18**, 161

Yamaguchi, H., see Uchida, K. **18**, 167
Yamaguchi, S., see Mori, N. **18**, 451
Yamaji, S., see Matsumoto, F. **18**, 471
Yamaji, S., see Totsuka, K. **18**, 477
Yamaji, S., see Totsuka, K. **18**, 463
Yamaji, S., see Yanagawa, A. **18**, 483
Yanagawa, A., J. Shimada, N. Mori, T. Sugihara, A. Sakai, S. Yamaji, K. Yano, T. Kitamura and T. Kano, Effects of gastrointestinal stimulant and suppressant pretreatment on the pharmacokinetics of AS-924, a novel ester-type cephem antibiotic **18**, 483
Yanagihara, R., see Zheng, X. **18**, 373
Yano, K., see Matsumoto, F. **18**, 471
Yano, K., see Yanagawa, A. **18**, 483
Yokota, N., see Uchida, K. **18**, 167
Yoo, Y.-J., see Choi, B.-K. **18**, 553
Yoshimi, A., see Mori, N. **18**, 451

Zarazaga, M., see Sáenz, Y. **18**, 353
Zhang, Y.L., J.T. Li and M.W. Zhao, Detection of amp C in *Enterobacter cloacae* in China **18**, 365
Zhao, M.W., see Zhang, Y.L. **18**, 365
Zheng, X., C. Johnson, Y. Lu, R. Yanagihara, S. Hollingshead, M. Crain, W. Benjamin, Jr. and K.B. Waites, Clinical isolates of *Streptococcus pneumoniae* resistant to levofloxacin contain mutations in both *gyrA* and *parC* genes **18**, 373
Zolfo, M., see Visconti, E. **18**, 547
Zvia, H., see Doron, S. **18**, 575